CD96 and coronary artery disorder: This study, which focused on immune checkpoint molecules in individuals with CAD, found that CAD Mφ express high levels of the immunoinhibitory molecule CD155, which binds CD96 and TIGIT expressed on CD4+ T cells and sends stop signals to the interacting T cell.